MedTrace Logo

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

NCT06765317 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2026-04-30

No results posted yet for this study

Summary

The researchers are doing this study to find out if the study treatment is an effective treatment that causes few or mild side effects in people with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), or transformed lymphoma. The treatment being tested in this study is glofitamab, polatuzumab, and obinutuzumab in combination with standard treatment (the combination of rituximab, cyclophosphamide, doxorubicin, and prednisone, or R-miniCHP).

Conditions

  • Diffuse Large B Cell Lymphoma (DLBCL)
  • High Grade B Cell Lymphoma

Interventions

DRUG

Glofitamab

C1D8 2.5 mg iv; C1D15 10 mg iv; C2D1-onwards: 30 mg iv, every 3 weeks

DRUG

Polatuzumab

1.8 mg/kg iv C1D1 onwards, every 3 weeks

DRUG

Rituximab

375 mg/m2 iv D1

DRUG

Cyclophosphamide

400 mg/m2 iv D1

DRUG

Doxorubicin

25 mg/m2 iv D1

DRUG

Obinutuzumab:

1000 mg iv C1D1 (7 days prior to glofitamab administration) single dose

Sponsors & Collaborators

Principal Investigators

  • Pallawi Torka, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-16
Primary Completion
2028-01-31
Completion
2028-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06765317 on ClinicalTrials.gov